Aptorum logo

APM - Aptorum Share Price

$2.69 0.0  1.5%

Last Trade - 05/03/21

Sector
Healthcare
Size
Small Cap
Market Cap £59.1m
Enterprise Value £54.4m
Revenue £450k
Position in Universe 5163rd / 6651
Bullish
Bearish
Unlock APM Revenue
Momentum
Relative Strength (%)
1m -17.3%
3m
6m
1yr
Volume Change (%)
10d / 3m
Price vs... (%)
52w High -81.1%
50d MA
200d MA
Growth & Value
12m Forecast Rolling Industry Market
Valuation (ttm) Industry Market
Margin of Safety
Qualifying GuruScreens
Financial Summary
Year End 31st Dec 2014 2015 2016 2017 2018 2019 2020E 2021E CAGR / Avg
0.000 0.000 0.000 0.000 0.38 0.54 0.70 1.20
PEG
Profitability
ROA
%
%
Cashflow
Dividends
Balance Sheet
NFA
m
FINANCIAL BRIEF: : For the six months ended 30 June 2020, Aptorum GroupLtd revenues increased 36% to $327K. Net loss decreased 32%to $6.2M. Revenues reflect an increase in demand for theCompany's products and services due to favorable marketconditions. Lower net loss reflects Interest income(expense), net decrease of 96% to $144K (expense), Generaland administrative fees decrease of 36% to $2.1M (expense).
Health Trend(F-Score)
0 1 2 3 4 5 6 7 8 9
Bankruptcy Score(Z-Score)
Distress
Cautious
Safe
Earnings Manipulation Risk(M-Score)
Other Ratios
Recent History
Latest interim period vs. prior period Industry Market
3yr Compound Annual Growth Rate Industry Market
Graphical History

Revenue

APM Revenue Unlock APM Revenue

Net Income

APM Net Income Unlock APM Revenue

Normalised EPS

APM Normalised EPS Unlock APM Revenue

PE Ratio Range

APM PE Ratio Range Unlock APM Revenue

Dividend Yield Range

APM Dividend Yield Range Unlock APM Revenue
Analyst Forecasts
Price Target:
( below Price)
31st Dec 2021
31st Dec 2022
Est. Long Term Growth Rate: Net Profit
()
EPS
()
DPS
()
Net Profit
()
EPS
()
DPS
()
Consensus Estimate
1m Change
3m Change
Analyst Consensus
Strong Sell Sell Hold Buy Strong Buy
EPS 2019 /  2020
APM EPS Forecasts Unlock APM Revenue
Profile Summary

Aptorum Group Limited is a pharmaceutical company dedicated to the discovery, development and commercializing of therapeutic assets to treat diseases, particularly infectious diseases and cancers (including orphan oncology indications). Through the establishment of drug discovery platforms, it enables the discovery of new therapeutics assets through systematic screening of existing approved drug molecules, and microbiome-based research platform for treatments of metabolic diseases. In addition to this, the Company is also pursuing therapeutic and diagnostic projects in neurology, gastroenterology, metabolic disorders, women’s health and other disease areas. It also has projects focused on surgical robotics and natural supplement for women undergoing menopause and experiencing related symptoms.

Directors
Last Annual December 31st, 2019
Last Interim June 30th, 2020
Public Since December 18, 2018
No. of Shareholders: n/a
No. of Employees: 36
Sector Healthcare
Industry Pharmaceuticals
Index Nasdaq Composite ,
Exchange NASDAQ Global Market
Shares in Issue 30,388,740
Free Float (0.0%)
Eligible for
ISAs
SIPPs
APM Share Price Performance
Share Price
Bid - Ask
Low - High
Spread
Day's Change
Avg Volume
Open - Close
Range (12m)
Beta
Latest News for APM
Upcoming Events for APM
Frequently Asked Questions for Aptorum
What is the Aptorum share price?

As of 05/03/21, shares in Aptorum are trading at $2.69, giving the company a market capitalisation of £59.1m. This share price information is delayed by 15 minutes.

How has the Aptorum share price performed this year?

Shares in Aptorum are currently trading at $2.69 and the price has moved by -35.95% over the past 365 days. In terms of relative price strength - which takes into account the overall market trend - the Aptorum price has moved by -49.48% over the past year.

What are the analyst and broker recommendations for Aptorum?

Of the analysts with advisory recommendations for Aptorum, there are there are currently 0 "buy" , 0 "hold" and 0 "sell" recommendations. The overall consensus recommendation for Aptorum is Buy. You can view the full broker recommendation list by unlocking its StockReport.

When will Aptorum next release its financial results?

Aptorum is scheduled to issue upcoming financial results on the following dates:

Interim results are scheduled for: 2021-06-30
What is the Aptorum dividend yield?

Aptorum does not currently pay a dividend.

Does Aptorum pay a dividend?

Aptorum does not currently pay a dividend.

When does Aptorum next pay dividends?

Aptorum does not currently pay a dividend.

How do I buy Aptorum shares?

To buy shares in Aptorum you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.

What is the market cap of Aptorum?

Shares in Aptorum are currently trading at $2.69, giving the company a market capitalisation of £59.1m.

Where are Aptorum shares listed? Where are Aptorum shares listed?

Here are the trading details for Aptorum:

Country of listing: United States
Exchange: NMQ
Ticker Symbol: APM
What kind of share is Aptorum?

Based on an overall assessment of its quality, value and momentum, Aptorum is currently classified as a Sucker Stock. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.

Is there a Aptorum share price forecast 2021?

Shares in Aptorum are currently priced at $2.69. At that level they are trading at 0.383% discount to the analyst consensus target price of 0.00.

Analysts covering Aptorum currently have a consensus Earnings Per Share (EPS) forecast of -0.61 for the next financial year.

How can I tell whether the Aptorum share price will go up?

An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Aptorum. Over the past six months, the relative strength of its shares against the market has been 48.65%. At the current price of $2.69, shares in Aptorum are trading at -8.06% against their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.

What is the Aptorum PE Ratio?

We were not able to find PE ratio data for Aptorum.

Who are the key directors of Aptorum?

Aptorum's management team is headed by:

Ian Huen - CEO
Darren Lui - PRE
Clark Cheng - EDR
Sabrina Khan - CFO
Thomas Lee - OTH
Angel Ng - COO
Charles Bathurst - NID
Mirko Scherer - NID
Justin Wu - NID
Douglas Arner - NID
Who are the major shareholders of Aptorum?

Here are the top five shareholders of Aptorum based on the size of their shareholding:

Huen (Ian) Individual Investor
Percentage owned: 20% (2.32m shares)
Lui (Darren) Individual Investor
Percentage owned: 4.64% (537k shares)
Wu (Justin) Individual Investor
Percentage owned: 1.78% (207k shares)
Schonfeld Strategic Advisors LLC Hedge Fund
Percentage owned: 0.39% (45.1k shares)
Morgan Stanley & Co. LLC Research Firm
Percentage owned: 0.28% (32.4k shares)
Similar to APM
© Stockopedia 2021, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.